ArticleBritish journal of cancer2022

CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.

Stefanie Seitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.